Aerie Pharmaceuticals, Inc. (AERI) Holdings Maintained by Advisory Research Inc.

Advisory Research Inc. continued to hold its stake in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) during the second quarter, according to its most recent filing with the SEC. The firm owned 19,427 shares of the company’s stock at the end of the second quarter. Advisory Research Inc. owned 0.05% of Aerie Pharmaceuticals worth $881,000 at the end of the most recent quarter.

Several other institutional investors have also recently modified their holdings of the company. DAFNA Capital Management LLC grew its position in shares of Aerie Pharmaceuticals by 128.3% during the second quarter. DAFNA Capital Management LLC now owns 106,770 shares of the company’s stock valued at $5,611,000 after purchasing an additional 60,000 shares in the last quarter. Kazazian Asset Management LLC purchased a new position in shares of Aerie Pharmaceuticals during the second quarter valued at about $450,000. Macquarie Group Ltd. purchased a new position in shares of Aerie Pharmaceuticals during the second quarter valued at about $610,000. Sectoral Asset Management Inc grew its position in shares of Aerie Pharmaceuticals by 3.4% during the second quarter. Sectoral Asset Management Inc now owns 402,674 shares of the company’s stock valued at $21,161,000 after purchasing an additional 13,251 shares in the last quarter. Finally, Tudor Investment Corp ET AL purchased a new position in shares of Aerie Pharmaceuticals during the second quarter valued at about $502,000. Hedge funds and other institutional investors own 94.64% of the company’s stock.

TRADEMARK VIOLATION WARNING: This news story was reported by Ticker Report and is the sole property of of Ticker Report. If you are accessing this news story on another website, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The original version of this news story can be viewed at https://www.tickerreport.com/banking-finance/2957411/aerie-pharmaceuticals-inc-aeri-holdings-maintained-by-advisory-research-inc.html.

A number of research analysts have recently weighed in on the company. Mizuho restated a “buy” rating and set a $70.00 price objective on shares of Aerie Pharmaceuticals in a research report on Monday, October 2nd. Canaccord Genuity set a $65.00 price objective on Aerie Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, August 8th. HC Wainwright set a $69.00 price objective on Aerie Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, August 2nd. Stifel Nicolaus restated a “buy” rating and set a $70.00 price objective on shares of Aerie Pharmaceuticals in a research report on Friday, July 28th. Finally, Cowen and Company restated a “buy” rating on shares of Aerie Pharmaceuticals in a research report on Thursday, October 5th. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and eleven have assigned a buy rating to the stock. Aerie Pharmaceuticals presently has an average rating of “Buy” and an average price target of $67.46.

Aerie Pharmaceuticals (NASDAQ:AERI) last released its quarterly earnings results on Tuesday, August 1st. The company reported ($0.82) earnings per share for the quarter, topping the consensus estimate of ($0.84) by $0.02.

Aerie Pharmaceuticals Company Profile

Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).

Want to see what other hedge funds are holding AERI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aerie Pharmaceuticals, Inc. (NASDAQ:AERI).

Institutional Ownership by Quarter for Aerie Pharmaceuticals (NASDAQ:AERI)

Receive News & Ratings for Aerie Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2017 Ticker Report. Google+.